These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32767531)

  • 1. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
    Vollmer BL; Wallach AI; Corboy JR; Dubovskaya K; Alvarez E; Kister I
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1477-1487. PubMed ID: 32767531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.
    Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H
    J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of hospitalization due to infection in rituximab-treated MS patients.
    Karlowicz JR; Klakegg M; Aarseth JH; Bø L; Myhr KM; Torgauten HM; Torkildsen Ø; Wergeland S
    Mult Scler Relat Disord; 2023 Mar; 71():104556. PubMed ID: 36842313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases.
    Rigal J; Ciron J; Lépine Z; Biotti D
    Mult Scler Relat Disord; 2020 Jun; 41():102019. PubMed ID: 32151983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
    McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
    JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany.
    Kümpfel T; Thiel S; Meinl I; Ciplea AI; Bayas A; Hoffmann F; Hofstadt-van Oy U; Hoshi M; Kluge J; Ringelstein M; Aktas O; Stoppe M; Walter A; Weber MS; Ayzenberg I; Hellwig K
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33334856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
    Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
    Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
    Shaygannejad V; Fayyazi E; Badihian S; Mirmosayyeb O; Manouchehri N; Ashtari F; Asgari N
    J Neurol; 2019 Mar; 266(3):642-650. PubMed ID: 30635724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
    Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease.
    AbdelRazek MA; Casasola M; Mollashahi R; Brodski A; Morin S; Augustynowicz A; Jassim S; Matiello M; Sloane J
    Mult Scler Relat Disord; 2022 Mar; 59():103505. PubMed ID: 35121247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience.
    Kim SH; Park NY; Kim KH; Hyun JW; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35853752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections.
    Langer-Gould A; Li BH; Smith JB; Xu S
    Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200211. PubMed ID: 38507657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
    Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropaenia complications from Ocrelizumab and Rituximab treatment.
    Pang V; Seery N; Wesselingh R; Yeh W; Zhong M; Tan T; Dwyer C; Nesbitt C; Rath L; Perera D; Bridge F; Skibina O; Bosco JJ; Jokubaitis V; Marriott M; Butkueven H; Van Der Walt A; Massey J; Sutton I; Monif M
    Mult Scler Relat Disord; 2024 Jan; 81():105147. PubMed ID: 38043368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
    Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
    Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.
    Radaelli M; Moiola L; Sangalli F; Esposito F; Barcella V; Ferrè L; Rodegher M; Colombo B; Fazio R; Martinelli V; Comi G
    Mult Scler; 2016 Apr; 22(4):511-9. PubMed ID: 26199350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
    Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
    Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.